Perfil de Expresión de los Receptores de Hormonas Esteroides Sexuales y de TGF-βRII en Cáncer Epitelial de Ovario
Epithelial Ovarian Cancer (EOC) is the most lethal gynecologic neoplasia since it is most commonly detected in an advanced stage, and often recurs after treatment, mainly because of the development of drug resistance (chemoresistance). EOC is clearly associated to hormonal and reproductive factors;...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis de maestría |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | México |
| Institución: | Universidad Autónoma Metropolitana |
| Repositorio: | Repositorio Institucional de la UAM Iztapalapa |
| Idioma: | español |
| OAI Identifier: | oai:bindani.izt.uam.mx:5x21tf42q |
| Acceso en línea: | https://doi.org/10.24275/uami.5x21tf42q |
| Access Level: | acceso abierto |
| Palabra clave: | info:eu-repo/classification/LEM/Progesterone info:eu-repo/classification/LEM/Estrogen info:eu-repo/classification/LEM/Hormonas esteroides info:eu-repo/classification/LEM/Andrógenos info:eu-repo/classification/LEM/Ovaries -- Tumors info:eu-repo/classification/LEM/Ovarios -- Tumores info:eu-repo/classification/LEM/Steroid hormones info:eu-repo/classification/LEM/Progesterona info:eu-repo/classification/LEM/Androgens info:eu-repo/classification/LEM/Estrógeno info:eu-repo/classification/cti/2 |
| Sumario: | Epithelial Ovarian Cancer (EOC) is the most lethal gynecologic neoplasia since it is most commonly detected in an advanced stage, and often recurs after treatment, mainly because of the development of drug resistance (chemoresistance). EOC is clearly associated to hormonal and reproductive factors; however, no relationship has been found between the expressions of steroid hormone receptors and this pathology, since most studies do not take into account the expression of the hormone receptors in tumor cells, specifically the estrogen, androgen and/or progesterone receptors (ER, AR, PR respectively) status related to histologic subtypes and metastatic disease progression. On the other hand, it is well known that Transforming Growth Factor-beta (TGFβ) plays an important role in ovarian tumorigenesis, and its expression also regulates proliferation, migration and tumor cell metastasis; accordingly, type II TGF-β receptor (TGF-βRII) can be used as a predictive and prognostic molecular ovarian cancer biomarker, and an aid for selecting optimally effective treatment(s) for recurrent EOC. The objective of this study was to investigate whether tumor expression of the AR, ER, PR and TGF- βRII was associated with histologic subtypes of EOC and malignant degree, determined by the Ki-67 labeling index and the tumor grade. The expression of all four receptors was inversely correlated with the malignant degree of the serous subtype of ovarian carcinoma. Decreased expression of ERα and the active form of pTGF-βRII may be used as molecular markers in this specific subtype of EOC. Moreover, since all poorly differentiated endometrioid tumors demonstrated no expression of TGF-βRII, our findings allow the proposal of a novel tumor marker (TGF-βRII/Ki-67 ratio) in order to confirm malignant degree. Our results could be useful for improving diagnostic accuracy in ovarian cancer and are a promising approach for more specific and less aggressive treatments against human EOC |
|---|